Can a Low-Dose steroid tame Immunotherapy's liver side effect?

NCT ID NCT07167251

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether low-dose prednisolone (a steroid) can safely treat liver inflammation (hepatitis) caused by immune checkpoint inhibitors in cancer patients. Researchers will enroll 63 adults with grade 2 or 3 immune-related hepatitis and give them 0.5-1 mg/kg of prednisolone daily. The goal is to see if this low dose resolves the liver problem within 8 weeks without needing stronger drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prednisolone (low-dose corticosteroid)
What this could lead to: If successful, this could show that low-dose steroids are enough to control immune-related hepatitis, reducing the need for stronger immunosuppressants.
What could go wrong: This is a small, early-stage registry study with only 63 participants, so results may not apply broadly. The treatment may not work for all patients or could require dose escalation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER IMMUNE-MEDIATED HEPATITIS IMMUNE-RELATED ADVERSE EVENTS

Contacts and locations

Locations

Royal Marsden Hospital
NOT_YET_RECRUITING

London, SW3 6JJ, United Kingdom
University Hospital Basel
RECRUITING

Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.